Does rabbit anti-thymocyte globulin dose and antiviral prophylaxis alter the risk of the development of PTLD in renal transplant population?
Ren Fail
.
2020 Nov;42(1):673-674.
doi: 10.1080/0886022X.2020.1792927.
Authors
Mahmoud Mohamed
1
2
3
,
Mohamed A Ghonim
4
5
,
Mai M Abouzeid
6
7
,
Maria Aurora Posadas Salas
8
9
10
Affiliations
1
Nephrology Division, Department of Medicine.
2
University of Tennessee Health Science Center.
3
Memphis, TN, USA.
4
St. Jude Children's Research Hospital, Memphis, TN, USA.
5
Department of Immunology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
6
Louisiana State University Health Sciences Center.
7
New Orleans, LA, USA.
8
Division of Nephrology and Hypertension, Department of Medicine.
9
Medical University of South Carolina.
10
Charleston, SC, USA.
PMID:
32662315
PMCID:
PMC7470055
DOI:
10.1080/0886022X.2020.1792927
No abstract available
Publication types
Letter
Comment
MeSH terms
Antilymphocyte Serum
Antiviral Agents
Humans
Immunosuppressive Agents
Kidney Transplantation*
Lymphoproliferative Disorders*
Substances
Antilymphocyte Serum
Antiviral Agents
Immunosuppressive Agents